Journey Medical Corporation develops and commercializes pharmaceutical products for the treatment of dermatological conditions. It markets generic prescription drugs for dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
IPO Year: 2021
Exchange: NASDAQ
Website: journeymedicalcorp.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
8/22/2024 | $9.00 | Buy | Rodman & Renshaw |
6/28/2024 | $11.00 | Buy | ROTH MKM |
2/25/2022 | $9.00 | Overweight | Cantor Fitzgerald |
12/16/2021 | $15.00 | Buy | Roth Capital |
12/7/2021 | $14.00 | Buy | B. Riley Securities |
SCHEDULE 13G/A - Journey Medical Corp (0001867066) (Subject)
10-Q - Journey Medical Corp (0001867066) (Filer)
8-K - Journey Medical Corp (0001867066) (Filer)
SCHEDULE 13G - Journey Medical Corp (0001867066) (Subject)
DEFA14A - Journey Medical Corp (0001867066) (Filer)
DEF 14A - Journey Medical Corp (0001867066) (Filer)
PRE 14A - Journey Medical Corp (0001867066) (Filer)
8-K - Journey Medical Corp (0001867066) (Filer)
10-K - Journey Medical Corp (0001867066) (Filer)
8-K - Journey Medical Corp (0001867066) (Filer)